Herpes Simplex Virus

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 1713-1730.e6

  Schiffer, Joshua T ^a,b   Corey, Lawrence ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acyclovir; Bell's palsy; Encephalitis; Genital herpes; Herpes labialis; Herpes simplex virus types 1 and 2 (HSV 1, HSV 2); Latency; Neonatal HSV; Suppression of genital herpes

Indexed keywords

EID: 84944608255     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00138-7     Document Type: Chapter

References (476)

1. Wildy P Herpes history and classification. The Herpes Viruses 1973, 1-25. Academic, New York. A. Kaplan (Ed.).
2. Astruc J De Morbis Venereis Libri Sex 1736, Paris.
3. Hutfield D History of herpes genitalis. Br J Vener Dis 1996, 42:263.
4. Parker FNR Studies on filterable viruses, II. Cultivation of herpes virus. Am J Pathol 1925, 1:337.
5. Lipschutz B Untersuchungen uber die Aetiologie der Krankheiten der Herpes Gruppe (herpes zoster, herpes genitalis, herpes febrillis). Arch Dermatol Symp (Berl) 1921, 136:428.
6. Nahmias AJ, Dowdle WR Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol 1968, 10:110-159.
7. Roizman B The structure and isomerization of herpes simplex virus genomes. Cell 1979, 16:481-494.
8. Dolan A, Jamieson FE, Cunningham C, et al. The genome sequence of herpes simplex virus type 2. J Virol 1998, 72:2010-2021.
9. Gentry GA, Lowe M, Alford G, et al. Sequence analyses of herpesviral enzymes suggest an ancient origin for human sexual behavior. Proc Natl Acad Sci U S A 1988, 85:2658-2661.
10. Buchman TG, Roizman B, Adams G, et al. Restriction endonuclease fingerprinting of herpes simplex virus DNA: a novel epidemiological tool applied to a nosocomial outbreak. J Infect Dis 1978, 138:488-498.
11. Schmidt OW, Fife KH, Corey L Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis 1984, 149:645-646.
12. Buchman TG, Roizman B, Nahmias AJ Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis 1979, 140:295-304.
13. Douglas J, Schmidt O, Corey L Acquisition of neonatal HSV-1 infection from a paternal source contact. J Pediatr 1983, 103:908-910.
14. Hammer SM, Buchman TG, D'Angelo LJ, et al. Temporal cluster of herpes simplex encephalitis: investigation by restriction endonuclease cleavage of viral DNA. J Infect Dis 1980, 141:436-440.
15. Lakeman AD, Nahmias AJ, Whitley RJ Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis 1986, 13:61-66.
16. Szpara ML, Parsons L, Enquist LW Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol 2010, 84:5303-5313.
17. Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994, 169:1338-1341.
18. Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196:266-270.
19. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007, 110:3071-3077.
20. Struyf F, Posavad CM, Keyaerts E, et al. Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. J Infect Dis 2002, 185:36-44.
21. Haarr L, Shukla D, Rødahl E, et al. Transcription from the gene encoding the herpesvirus entry receptor nectin-1 (HveC) in nervous tissue of adult mouse. Virology 2001, 287:301-309.
22. Mata M, Zhang M, Hu X, et al. HveC (nectin-1) is expressed at high levels in sensory neurons, but not in motor neurons, of the rat peripheral nervous system. J Neurovirol 2001, 7:476-480.
23. Zelus BD, Stewart RS, Ross J The virion host shutoff protein of herpes simplex virus type 1: messenger ribonucleolytic activity in vitro. J Virol 1996, 70:2411-2419.
24. Katsumata K, Weinberg A, Chono K, et al. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 2012, 56:3587-3591.
25. Birkmann A, Kropeit D, McCormick D, et al. Safety and HUMAN Pharmacokinetics of AIC316, a potent helicase-primase inhibitor of herpes simplex virus 2011, Presented at the 24th International Conference on Antiviral Research. Sofia, Bulgaria.
26. Homa FL, Brown JC Capsid assembly and DNA packaging in herpes simplex virus. Rev Med Virol 1997, 7:107-122.
27. Roizman B, Knipe DM Herpes Simplex Viruses and Their Replication 2007, Lippincott Williams & Wilkins, Philadelphia. 5th ed.
28. Stevens JG, Cook ML Latent herpes simplex virus in spinal ganglia of mice. Science 1971, 173:843-845.
29. Cushing H Surgical aspects of major neuralgia of trigeminal nerve: report of 20 cases of operation upon the gasserian ganglion with anatomic and physiologic notes on the consequences of its removal. JAMA 1905, 44:773-779.
30. Stevens JG, Haarr L, Porter DD, et al. Prominence of the herpes simplex virus latency-associated transcript in trigeminal ganglia from seropositive humans. J Infect Dis 1988, 158:117-123.
31. Mehta A, Maggioncalda J, Bagasra O, et al. In situ DNA PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice. Virology 1995, 206:633-640.
32. Burke RL, Hartog K, Croen KD, et al. Detection and characterization of latent HSV RNA by in situ and Northern blot hybridization in guinea pigs. Virology 1991, 181:793-797.
33. Saksena MM, Wakisaka H, Tijono B, et al. Herpes simplex virus type 1 accumulation, envelopment, and exit in growth cones and varicosities in mid-distal regions of axons. J Virol 2006, 80:3592-3606.
34. Granstedt AE, Brunton BW, Enquist LW Imaging the transport dynamics of single alphaherpesvirus particles in intact peripheral nervous system explants from infected mice. MBio 2013, 4:e00358-13.
35. Baringer JR Recovery of herpes simplex virus from human sacral ganglions. N Engl J Med 1974, 291:828-830.
36. Sawtell N, Thompson R Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol 1992, 66:2150-2156.
37. Sawtell NM, Thompson RL Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol 1992, 66:2157-2169.
38. Carton CA, Kilbourne ED Activation of latent herpes simplex by trigeminal sensory-root section. N Engl J Med 1952, 246:172-176.
39. Wang K, Mahalingam G, Hoover S, et al. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia. J Virol 2007, 81:6817-6826.
40. van Velzen M, van Loenen FB, Meesters RJ, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012, 205:1539-1543.
41. Javier RT, Stevens JG, Dissette VB, et al. A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state. Virology 1988, 166:254-257.
42. Yoshikawa T, Hill JM, Stanberry LR, et al. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med 1996, 184:659-664.
43. Krause PR, Stanberry LR, Bourne N, et al. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med 1995, 181:297-306.
44. Nicoll MP, Proenca JT, Connor V, et al. Influence of herpes simplex virus 1 latency-associated transcripts on the establishment and maintenance of latency in the ROSA26R reporter mouse model. J Virol 2012, 86:8848-8858.
45. Thompson RL, Sawtell NM Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J Virol 2001, 75:6660-6675.
46. Perng GC, Jones C, Ciacci-Zanella J, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000, 287:1500-1503.
47. Tang S, Bertke AS, Patel A, et al. An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A 2008, 105:10931-10936.
48. Du T, Zhou G, Roizman B HSV-1 gene expression from reactivated ganglia is disordered and concurrent with suppression of latency-associated transcript and miRNAs. Proc Natl Acad Sci U S A 2011, 108:18820-18824.
49. Schiffer JT, Corey L Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 2013, 19:280-290.
50. Schiffer JT, Abu-Raddad L, Mark KE, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med 2009, 1:7-16.
51. Wang K, Lau T, Morales M, et al. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal ganglia at the single-cell level. J Virol 2005, 79:14079-14087.
52. Chen X, Mata M, Kelley M, et al. The relationship of herpes simplex virus latency associated transcript expression to genome copy number: a quantitative study using laser capture microdissection. J Neurovirol 2002, 8:204-210.
53. Catez F, Picard C, Held K, et al. HSV-1 genome subnuclear positioning and associations with host-cell PML-NBs and centromeres regulate LAT locus transcription during latency in neurons. PLoS Pathog 2012, 8:e1002852.
54. Cliffe AR, Coen DM, Knipe DM Kinetics of facultative heterochromatin and polycomb group protein association with the herpes simplex viral genome during establishment of latent infection. MBio 2013, 4:e00590-12.
55. Knipe DM, Lieberman PM, Jung JU, et al. Snapshots: chromatin control of viral infection. Virology 2013, 435:141-156.
56. Schiffer JT, Aubert M, Weber ND, et al. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 2012, 86:8920-8936.
57. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998, 178:1795-1798.
58. Malkin JE, Morand P, Malvy D, et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sex Transm Infect 2002, 78:201-203.
59. Tunback P, Bergstrom T, Andersson AS, et al. Prevalence of herpes simplex virus antibodies in childhood and adolescence: a cross-sectional study. Scand J Infect Dis 2003, 35:498-502.
60. Xu F, Sternberg M, Kottiri B, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
61. Cowan FM, Copas A, Johnson AM, et al. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence?. Sex Transm Infect 2002, 78:346-348.
62. Kropp R, Wong T, Cormier L, et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006, 117:1955-1962.
63. Vyse AJ, Gay NJ, Slomka MJ, et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000, 76:183-187.
64. Bernstein DI, Bellamy AR, Hook EW, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013, 56:344-351.
65. Cowan FM, Johnson AM, Ashley R, et al. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994, 309:1325-1329.
66. Fleming D, McQuillan G, Johnson R, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997, 337:1105-1111.
67. Weiss H Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004, 11(suppl 1):24A-35A.
68. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305:1441-1449.
69. Mugo N, Dadabhai SS, Bunnell R, et al. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya. Sex Transm Dis 2011, 38:1059-1066.
70. Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989, 321:7-12.
71. Andrasik MP, Chapman CH, Clad R, et al. Developing concurrency messages for the black community in Seattle, Washington. AIDS Educ Prev 2012, 24:527-548.
72. Corey L, Wald A, Celum C, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004, 35:435-445.
73. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex Transm Dis 1990, 17:90-94.
74. Cherpes TL, Meyn LA, Krohn MA, et al. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis 2003, 30:405-410.
75. Looker KJ, Garnett GP, Schmid GP An estimate of the glo®bal prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86:805-812.
76. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999, 341:1432-1438.
77. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
78. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999, 282:331-340.
79. Wald A, Langenberg A, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001, 285:3100-3106.
80. Gottlieb SL, Douglas JM, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004, 190:1059-1067.
81. Kebede Y, Dorigo-Zetsma W, Mengistu Y, et al. Transmission of herpes simplex virus type 2 among factory workers in Ethiopia. J Infect Dis 2004, 190:365-372.
82. Kamali A, Nunn A, Mulder D, et al. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect 1999, 75:98-102.
83. McFarland W, Gwanzura L, Bassett M, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999, 180:1459-1465.
84. Okuku HS, Sanders EJ, Nyiro J, et al. Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sex Transm Dis 2011, 38:837-844.
85. Tobian AA, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis 2009, 199:945-949.
86. Schiffer JT, Wald A, Selke S, et al. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011, 204:554-561.
87. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
88. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985, 12:33-39.
89. Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006, 194:42-52.
90. Weiss H, Thomas S, Munabi S, et al. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006, 82:101-109.
91. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009, 199:958-964.
92. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360:1298-1309.
93. Tobian AA, Kigozi G, Redd AD, et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. J Infect Dis 2012, 205:486-490.
94. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000, 342:844-850.
95. Blank H, Haines HG Experimental human reinfection with herpes simplex virus. J Invest Dermatol 1973, 61:223-225.
96. Cherpes TL, Meyn LA, Hillier SL Cunnilingus and vaginal intercourse are risk factors for herpes simplex virus type 1 acquisition in women. Sex Transm Dis 2005, 32:84-89.
97. Perl TM, Haugen TH, Pfaller MA, et al. Transmission of herpes simplex virus type 1 infection in an intensive care unit. Ann Intern Med 1992, 117:584-586.
98. Belongia EA, Goodman JL, Holland EJ, et al. An outbreak of herpes gladiatorum at a high-school wrestling camp. N Engl J Med 1991, 325:906-910.
99. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509-515.
100. Quinn TC, Corey L, Chaffee RG, et al. The etiology of anorectal infections in homosexual men. Am J Med 1981, 71:395-406.
101. Gray R, Wawer M, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149-1153.
102. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011, 3:77ra29.
103. Schiffer JT, Swan D, Al Sallaq R, et al. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. Elife 2013, 2:e00288.
104. Schiffer JT, Magaret A, Selke S, et al. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother 2011, 66:2593-2600.
105. Sacks SL, Griffiths PD, Corey L, et al. Introduction: is viral shedding a surrogate marker for transmission of genital herpes?. Antiviral Res 2004, 63(suppl 1):S3-S9.
106. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141-1149.
107. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr 2010, 54:482-488.
108. Blower S, Wald A, Gershengorn H, et al. Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis 2004, 190:1610-1617.
109. Kim H, Wald A, Harris J, et al. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis 2008, 35:124-128.
110. Stanberry LR, Kern ER, Richards JT, et al. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 1982, 146:397-404.
111. Sawtell NM Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation. J Virol 2003, 77:4127-4138.
112. Rock DL, Fraser NW Detection of HSV-1 genome in central nervous system of latently infected mice. Nature 1983, 302:523-525.
113. Ohashi M, Bertke AS, Patel A, Krause PR Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia. J Virol 2011, 85:3030-3032.
114. Feldman LT, Ellison AR, Voytek CC, et al. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 2002, 99:978-983.
115. Corey L, Spear PG Infections with herpes simplex viruses (1). N Engl J Med 1986, 314:686-691.
116. Johnston C, Magaret A, Selke S, et al. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008, 198:31-34.
117. Verjans GM, Hintzen RQ, van Dun JM, et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 2007, 104:3496-3501.
118. Van Velzen M, Jing L, Osterhaus A, et al. Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia. PLoS Pathog 2013, 9:e1003547.
119. Chen S, Garber D, Schaffer P, et al. Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation. Virology 2000, 278:207-216.
120. Liu T, Khanna K, Carriere B, et al. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001, 75:11178-11184.
121. Liu T, Khanna K, Chen X, et al. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191:1459-1466.
122. Decman V, Kinchington PR, Harvey SA, et al. Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression. J Virol 2005, 79:10339-10347.
123. Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008, 322:268-271.
124. Hoshino Y, Qin J, Follmann D, et al. The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia. Virology 2008, 372:56-63.
125. Hoshino Y, Pesnicak L, Cohen JI, et al. Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells. J Virol 2007, 81:8157-8164.
126. Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature 2013, 497:494-497.
127. Cunningham AL, Turner RR, Miller AC, et al. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest 1985, 75:226-233.
128. Zhu J, Koelle D, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007, 204:595-603.
129. Peng T, Zhu J, Phasouk K, et al. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection. J Virol 2012, 86:10587-10596.
130. Koelle D, Posavad C, Barnum G, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101:1500-1508.
131. Koelle DM, Liu Z, McClurkan CM, et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002, 110:537-548.
132. Schiffer JT, Abu-Raddad L, Mark KE, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010, 107:18973-18978.
133. Posavad CM, Koelle DM, Shaughnessy MF, et al. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997, 94:10289-10294.
134. Posavad C, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004, 190:693-696.
135. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009, 15:886-892.
136. Schiffer JT Mucosal HSV-2 specific CD8+ T-cells represent containment of prior viral shedding rather than a correlate of future protection. Front Immunol 2013, 4:209.
137. Crespi C, Cumberland W, Wald A, et al. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007, 83:359-364.
138. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997, 99:1092-1097.
139. Jerome KR, Fox R, Chen Z, et al. Inhibition of apoptosis by primary isolates of herpes simplex virus. Arch Virol 2001, 146:2219-2225.
140. York IA, Roop C, Andrews DW, et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994, 77:525-535.
141. Tigges MA, Koelle D, Hartog K, et al. Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol 1992, 66:1622-1634.
142. Murphy JA, Duerst RJ, Smith TJ, et al. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J Virol 2003, 77:9337-9345.
143. Barcy S, Corey L Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells. J Immunol 2001, 166:6242-6249.
144. Jerome KR, Chen Z, Lang R, et al. HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas. J Immunol 2001, 167:3928-3935.
145. Lin R, Noyce RS, Collins SE, et al. The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J Virol 2004, 78:1675-1684.
146. Sanchez R, Mohr I Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J Virol 2007, 81:3455-3464.
147. Abbo L, Vincek V, Dickinson G, et al. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Clin Infect Dis 2007, 44:e25-e27.
148. Dalloul A, Oksenhendler E, Chosidow O, et al. Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J Clin Virol 2004, 30:329-336.
149. Puel A, Reichenbach J, Bustamante J, et al. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am J Hum Genet 2006, 78:691-701.
150. Sancho-Shimizu V, Perez de Diego R, Lorenzo L, et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011, 121:4889-4902.
151. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314:308-312.
152. Sancho-Shimizu V, Zhang SY, Abel L, et al. Genetic susceptibility to herpes simplex virus 1 encephalitis in mice and humans. Curr Opin Allergy Clin Immunol 2007, 7:495-505.
153. Johnson JR, Egaas S, Gleaves CA, et al. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992, 14:38-45.
154. Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991, 163:1001-1007.
155. Modiano P, Salloum E, Gillet-Terver MN, et al. Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Br J Dermatol 1995, 133:475-478.
156. Leib DA Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr Top Microbiol Immunol 2002, 269:171-185.
157. Bochud PY, Magaret AS, Koelle DM, et al. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus type 2 infection. J Infect Dis 2007, 196:505-509.
158. Mark K, Corey L, Meng T, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007, 195:1324-1331.
159. Koelle DM, Magaret A, Warren T, et al. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex Transm Infect 2010, 86:202-206.
160. Koelle D, Corey L Herpes simplex: insights on patho®genesis and possible vaccines. Annu Rev Med 2008, 59:381-395.
161. Lund JM, Linehan MM, Iijima N, et al. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J Immunol 2006, 177:7510-7514.
162. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
163. Manickan E, Rouse BT Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. J Virol 1995, 69:8178-8179.
164. Koelle DM, Corey L Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003, 16:96-113.
165. Kapoor AK, Nash AA, Wildy P, et al. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity. J Gen Virol 1982, 60:225-233.
166. Smith CM, Belz GT, Wilson NS, et al. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003, 170:4437-4440.
167. Khanna KM, Bonneau RH, Kinchington PR, et al. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003, 18:593-603.
168. Jing L, Haas J, Chong TM, et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest 2012, 122:654-673.
169. Jing L, Schiffer JT, Chong TM, et al. CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence. J Virol 2013, 87:2617-2627.
170. Moss NJ, Magaret A, Laing KJ, et al. Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes. J Virol 2012, 86:9952-9963.
171. Koelle DM, Abbo H, Peck A, et al. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994, 169:956-961.
172. Cunningham AL, Merigan TC Gamma interferon production appears to predict time of recurrence of herpes labialis. J Immunol 1983, 130:2397-2400.
173. Nakanishi Y, Lu B, Gerard C, et al. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009, 462:510-513.
174. Brown Z, Wald A, Morrow R, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203-209.
175. Prober CG, Sullender WM, Yasukawa LL, et al. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med 1987, 316:240-244.
176. Brown EL, Morrow R, Krantz EM, et al. Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol 2006, 195:115-120.
177. Dubin G, Fishman NO, Eisenberg RJ, et al. The role of herpes simplex virus glycoproteins in immune evasion. Curr Top Microbiol Immunol 1992, 179:111-120.
178. Balachandran N, Bacchetti S, Rawls WE Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982, 37:1132-1137.
179. Mikloska Z, Sanna P, Cunningham A Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol 1999, 73:5934-5944.
180. Li Z, Palaniyandi S, Zeng R, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A 2011, 108:4388-4393.
181. Kwant-Mitchell A, Ashkar AA, Rosenthal KL Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J Virol 2009, 83:10664-10676.
182. Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011, 85:10472-10486.
183. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983, 98:958-972.
184. Reeves WC, Corey L, Adams HG, et al. Risk of recurrence after first episodes of genital herpes: relation to HSV type and antibody response. N Engl J Med 1981, 305:315-319.
185. Benedetti J, Corey L, Ashley R Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994, 121:847-854.
186. Bader C, Crumpacker CS, Schnipper LE, et al. The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis 1978, 138:897-905.
187. Glezen WP, Fernald GW, Lohr JA Acute respiratory disease of university students with special reference to the etiologic role of Herpesvirus hominis. Am J Epidemiol 1975, 101:111-121.
188. Schmitt DL, Johnson DW, Henderson FW Herpes simplex type 1 infections in group day care. Pediatr Infect Dis J 1991, 10:729-734.
189. Amir J, Harel L, Smetana Z, et al. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol 1999, 16:259-263.
190. Openshaw H, Bennett HE Recurrence of herpes simplex virus after dental extraction. J Infect Dis 1982, 146:707.
191. Pazin GJ, Armstrong JA, Lam MT, et al. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med 1979, 301:225-230.
192. Straus SE, Smith HA, Brickman C, et al. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982, 96:270-277.
193. Eisen D, Essell J, Broun ER, et al. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003, 31:51-55.
194. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981, 305:1439-1444.
195. Foley FD, Greenawald KA, Nash G, et al. Herpesvirus infection in burned patients. N Engl J Med 1970, 282:652-656.
196. Garland SM, Hill PJ Eczema herpeticum in pregnancy successfully treated with acyclovir. Aust N Z J Obstet Gynaecol 1994, 34:214-215.
197. Shelley W Herpes simplex virus as a cause of erythema multiforme. JAMA 1967, 210:153.
198. Orton PW, Huff JC, Tonnesen MG, et al. Detection of a herpes simplex viral antigen in skin lesions of erythema multiforme. Ann Intern Med 1984, 101:48-50.
199. Green JA, Spruance SL, Wenerstrom G, et al. Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir. Ann Intern Med 1985, 102:632-633.
200. Vahlne A, Edstrom S, Arstila P, et al. Bell's palsy and herpes simplex virus. Arch Otolaryngol 1981, 107:79-81.
201. Furuta Y, Fukuda S, Chida E, et al. Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. J Med Virol 1998, 54:162-166.
202. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007, 357:1598-1607.
203. Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007, 28:408-413.
204. Engstrom M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valacyclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008, 7:993-1000.
205. Bernstein D, Lovett M, Bryson Y Serologic analysis of first-episode nonprimary genital herpes simplex virus infection: presence of type 2 antibody in acute serum samples. Am J Med 1984, 77:1055-1060.
206. Engelberg R, Carrell D, Krantz E, et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003, 30:174-177.
207. Benedetti JK, Zeh J, Selke S, et al. Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus. Am J Med 1995, 98:237-242.
208. Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N Engl J Med 1983, 308:916-921.
209. Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983, 98:914-921.
210. Stamm WE, Wagner KF, Amsel R, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980, 303:409-415.
211. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992, 326:1533-1539.
212. Lehtinen M, Rantala I, Teisala K, et al. Detection of herpes simplex virus in women with acute pelvic inflammatory disease. J Infect Dis 1985, 152:78-82.
213. Morrisseau PM, Phillips CA, Leadbetter GW Viral prostatitis. J Urol 1970, 103:767-769.
214. Goodell SE, Quinn TC, Mkrtichian E, et al. Herpes simplex virus proctitis in homosexual men: clinical, sigmoidoscopic, and histopathological features. N Engl J Med 1983, 308:868-871.
215. Rompalo AM, Mertz GJ, Davis LG, et al. Oral acyclovir for treatment of first-episode herpes simplex virus proctitis. JAMA 1988, 259:2879-2881.
216. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:21-28.
217. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995, 333:770-775.
218. Whitley R, Barton N, Collins E, et al. Mucocutaneous herpes simplex virus infections in immunocompromised patients: a model for evaluation of topical antiviral agents. Am J Med 1982, 73:236-240.
219. Skoldenberg B, Jeansson S, Wolontis S Herpes simplex virus type 2 and acute aseptic meningitis: clinical features of cases with isolation of herpes simplex virus from cerebrospinal fluids. Scand J Infect Dis 1975, 7:227-232.
220. Schlesinger Y, Tebas P, Gaudreault-Keener M, et al. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995, 20:842-848.
221. Ravaut P, Darré M Les réactions nerveuses au cours de herpes genitaux. Ann Dermatol Syphiligr 1904, 5:481.
222. Brenton DW Hypoglycorrhachia in herpes simplex type 2 meningitis. Arch Neurol 1980, 37:317.
223. Bruyn GW, Straathof LJ, Raymakers GM Mollaret's meningitis: differential diagnosis and diagnostic pitfalls. Neurology 1962, 12:745-753.
224. Tedder DG, Ashley R, Tyler KL, et al. Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med 1994, 121:334-338.
225. Bergstrom T, Vahlne A, Alestig K, et al. Primary and recurrent herpes simplex virus type 2-induced meningitis. J Infect Dis 1990, 162:322-330.
226. Riehle RA, Williams JJ Transient neuropathic bladder following herpes simplex genitalis. J Urol 1979, 122:263-264.
227. Goldmeier D, Bateman JR, Rodin P Urinary retention and intestinal obstruction associated with ano-rectal herpes simplex virus infection. Br Med J 1975, 2:425.
228. Shturman-Ellstein R, Borkowsky W, Fish I, et al. Myelitis associated with genital herpes in a child. J Pediatr 1976, 88:523.
229. Diamond C, Mohan K, Hobson A, et al. Viremia in neonatal herpes simplex virus infections. Pediatr Infect Dis J 1999, 18:487-489.
230. Frederick DM, Bland D, Gollin Y Fatal disseminated herpes simplex virus infection in a previously healthy pregnant woman: a case report. J Reprod Med 2002, 47:591-596.
231. Moedy JL, Lerman SJ, White RJ Fatal disseminated herpes simplex virus infection in a healthy child. Am J Dis Child 1981, 135:45-47.
232. Friedman HM, Pincus T, Gibilisco P, et al. Acute monoarticular arthritis caused by herpes simplex virus and cytomegalovirus. Am J Med 1980, 69:241-247.
233. Whitaker JA, Hardison JE Severe thrombocytopenia after generalized herpes simplex virus-2 (HSV-2) infection. South Med J 1978, 71:864-865.
234. Flewett TH, Parker RG, Philip WM Acute hepatitis due to herpes simplex virus in an adult. J Clin Pathol 1969, 22:60-66.
235. Schlesinger JJ, Gandara D, Bensch KG Myoglobinuria associated with herpes-group viral infections. Arch Intern Med 1978, 138:422-424.
236. Goyette RE, Donowho EM, Hieger LR, et al. Fulminant herpesvirus hominis hepatitis during pregnancy. Obstet Gynecol 1974, 43:191-195.
237. Kobbermann T, Clark L, Griffin WT Maternal death secondary to disseminated herpesvirus hominis. Am J Obstet Gynecol 1980, 137:742-743.
238. Nahmias AJ Disseminated herpes-simplex-virus infections. N Engl J Med 1970, 282:684-685.
239. Sutton AL, Smithwick EM, Seligman SJ, et al. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med 1974, 56:545-553.
240. Kaul R, Nagelkerke N, Kimani J, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 2007, 196:1692-1697.
241. Sacks SL Frequency and duration of patient-observed recurrent genital herpes simplex virus infection: characterization of the nonlesional prodrome. J Infect Dis 1984, 150:873-877.
242. Frenkel LM, Garratty EM, Shen JP, et al. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993, 118:414-418.
243. Corey L, Holmes KK Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983, 98:973-983.
244. Diaz-Mitoma F, Ruben M, Sacks S, et al. Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. J Clin Microbiol 1996, 34:657-663.
245. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection: influence of site of infection and viral type. N Engl J Med 1987, 316:1444-1449.
246. Landry ML, Zibello TA Ability of herpes simplex virus (HSV) types 1 and 2 to induce clinical disease and establish latency following previous genital infection with the heterologous HSV type. J Infect Dis 1988, 158:1220-1226.
247. Sacks SL, Varner TL, Davies KS, et al. Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes. J Infect Dis 1990, 161:692-698.
248. Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997, 175:583-589.
249. Fast MV, D'Costa LJ, Nsanze H, et al. The clinical diagnosis of genital ulcer disease in men in the tropics. Sex Transm Dis 1984, 11:72-76.
250. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003, 188:1345-1351.
251. Chapel TA, Jeffries CD, Brown WJ Simultaneous infection with Treponema pallidum and herpes simplex virus. Cutis 1979, 24:191-192.
252. Langenberg A, Benedetti J, Jenkins J, et al. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989, 110:882-887.
253. Rand KH, Hoon EF, Massey JK, et al. Daily stress and recurrence of genital herpes simplex. Arch Intern Med 1990, 150:1889-1893.
254. Cone RW, Hobson AC, Brown Z, et al. Frequent reactivation of genital herpes simplex viruses among pregnant women. JAMA 1994, 272:792-796.
255. Krone MR, Tabet SR, Paradise M, et al. Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. J Infect Dis 1998, 178:978-982.
256. Wald A, Zeh J, Selke S, et al. Genital shedding of herpes simplex virus among men. J Infect Dis 2002, 186(suppl 1):S34-S39.
257. Benedetti JK, Zeh J, Corey L Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999, 131:14-20.
258. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis 2011, 203:180-187.
259. Bryson Y, Dillon M, Bernstein DI, et al. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993, 167:942-946.
260. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988, 157:1169-1177.
261. Rooney JF, Felser JM, Ostrove JM, et al. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 1986, 314:1561-1564.
262. Tata S, Johnston C, Huang ML, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis 2010, 201:499-504.
263. Gill MJ, Arlette J, Buchan K Herpes simplex virus infection of the hand: a profile of 79 cases. Am J Med 1988, 84:89-93.
264. Anderson BJ The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. Med Sci Sports Exerc 2003, 35:1809-1814.
265. Liesegang TJ, Melton LJ, Daly PJ, et al. Epidemiology of ocular herpes simplex: incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989, 107:1155-1159.
266. Cook SD Herpes simplex virus in the eye. Br J Ophthalmol 1992, 76:365-366.
267. Benz MS, Glaser JS, Davis JL Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003, 135:551-553.
268. Whitley RJ, Nahmias AJ, Visintine AM, et al. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 1980, 66:489-494.
269. Culbertson WW, Blumenkranz MS, Haines H, et al. The acute retinal necrosis syndrome. Part 2: Histopathology and etiology. Ophthalmology 1982, 89:1317-1325.
270. Holland GN Acquired immunodeficiency syndrome and ophthalmology: the first decade. Am J Ophthalmol 1992, 114:86-95.
271. Olson LC, Buescher EL, Artenstein MS, et al. Herpesvirus infections of the human central nervous system. N Engl J Med 1967, 277:1271-1277.
272. Whitley RJ, Lakeman F Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995, 20:414-420.
273. Whitley RJ, Soong SJ, Hirsch MS, et al. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med 1981, 304:313-318.
274. Fraser NW, Lawrence WC, Wroblewska Z, et al. Herpes simplex type 1 DNA in human brain tissue. Proc Natl Acad Sci U S A 1981, 78:6461-6465.
275. Whitley R, Lakeman AD, Nahmias A, et al. DNA restriction-enzyme analysis of herpes simplex virus isolates obtained from patients with encephalitis. N Engl J Med 1982, 307:1060-1062.
276. Whitley RJ, Cobbs CG, Alford CA, et al. Diseases that mimic herpes simplex encephalitis: diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA 1989, 262:234-239.
277. Aurelius E, Johansson B, Skoldenberg B, et al. Encephalitis in immunocompetent patients due to herpes simplex virus type 1 or 2 as determined by type-specific polymerase chain reaction and antibody assays of cerebrospinal fluid. J Med Virol 1993, 39:179-186.
278. Lakeman FD, Whitley RJ Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995, 171:857-863.
279. Rowley AH, Whitley RJ, Lakeman FD, et al. Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet 1990, 335:440-441.
280. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986, 314:144-149.
281. McBane RD, Gross JB Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 1991, 37:600-603.
282. McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985, 88:1111-1117.
283. Ramsey PG, Fife KH, Hackman RC, et al. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982, 97:813-820.
284. Cook CH, Yenchar JK, Kraner TO, et al. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg 1998, 176:357-360.
285. Graham BS, Snell JD Herpes simplex virus infection of the adult lower respiratory tract. Medicine (Baltimore) 1983, 62:384-393.
286. Camps K, Jorens PG, Demey HE, et al. Clinical significance of herpes simplex virus in the lower respiratory tract of critically ill patients. Eur J Clin Microbiol Infect Dis 2002, 21:758-759.
287. Prellner T, Flamholc L, Haidl S, et al. Herpes simplex virus-the most frequently isolated pathogen in the lungs of patients with severe respiratory distress. Scand J Infect Dis 1992, 24:283-292.
288. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995, 123:845-847.
289. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718-1725.
290. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002, 16:2425-2430.
291. van Velzen M, Ouwendijk WJ, Selke S, et al. Longitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIV. J Med Virol 2013, 85:1669-1677.
292. Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013, 208:839-846.
293. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections: the population-based AIDS in Multiethnic Neighborhoods Study. JAMA 1992, 268:1702-1708.
294. Freeman E, Weiss H, Glynn J, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73-83.
295. Albrecht MA, DeLuca NA, Byrn RA, et al. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 1989, 63:1861-1868.
296. Kucera LS, Leake E, Iyer N, et al. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990, 6:641-647.
297. Margolis D, Rabson A, Straus S, et al. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992, 186:788-791.
298. Mbopi Keou F, Grésenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999, 13:536-537.
299. Schacker T, Ryncarz A, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280:61-66.
300. Holmberg S, Stewart J, Gerber A, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988, 259:1048-1050.
301. Hook EW, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992, 165:251-255.
302. Serwadda D, Gray R, Sewankambo N, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003, 188:1492-1497.
303. Stamm W, Handsfield H, Rompalo A, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988, 260:1429-1433.
304. Brown J, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007, 21:1515-1523.
305. Abu-Raddad L, Magaret A, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008, 3:e2230.
306. Wald A, Link K Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002, 185:45-52.
307. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109-2119.
308. Watson-Jones D, Weiss H, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560-1571.
309. Quinn T, Wawer M, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.
310. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
311. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008, 198:241-249.
312. Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005, 106:1341-1348.
313. Drake A, John-Stewart G, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007, 109:403-409.
314. Nagot N, Ouédraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790-799.
315. Zuckerman R, Lucchetti A, Whittington W, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007, 196:1500-1508.
316. Perti T, Saracino M, Baeten JM, et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr 2013, 63:201-208.
317. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010, 375:824-833.
318. Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012, 12:441-448.
319. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362:427-439.
320. McMahon MA, Siliciano JD, Lai J, et al. The anti-herpetic drug acyclovir inhibits HIV replication and selects the V75i reverse transcriptase multi-drug resistance mutation. J Biol Chem 2008, 283:31289-31293.
321. Straus SE, Seidlin M, Takiff H, et al. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med 1984, 100:522-524.
322. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982, 96:265-269.
323. Meyers JD, Flournoy N, Thomas ED Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980, 142:338-346.
324. Ringden O, Heimdahl A, Lonnqvist B, et al. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1984, 1:744.
325. Nichols WG, Boeckh M, Carter RA, et al. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. J Infect Dis 2003, 187:801-808.
326. Andrei G, Georgala A, Topalis D, et al. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis 2013, 207:1295-1305.
327. Krawczyk A, Arndt MA, Grosse-Hovest L, et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A 2013, 110:6760-6765.
328. Katsumata K, Chono K, Kato K, et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother 2013, 57:1339-1346.
329. Arvin AM, Hensleigh PA, Prober CG, et al. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med 1986, 315:796-800.
330. Florman AL, Gershon AA, Blackett PR, et al. Intrauterine infection with herpes simplex virus: resultant congenital malformations. JAMA 1973, 225:129-132.
331. Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991, 164:289-293.
332. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991, 324:450-454.
333. Corey L, Whitley RJ, Stone EF, et al. Difference in neurologic outcome after antiviral therapy of neonatal central nervous system herpes simplex virus type 1 versus herpes simplex virus type 2 infection. Lancet 1988, 2:1-4.
334. Arvin AM, Yeager AS, Bruhn FW, et al. Neonatal herpes simplex infection in the absence of mucocutaneous lesions. J Pediatr 1982, 100:715-721.
335. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001, 108:230-238.
336. Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 2011, 365:1284-1292.
337. Forsgren M, Skoog E, Jeansson S, et al. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. Int J STD AIDS 1994, 5:113-116.
338. Xu F, Markowitz LE, Gottlieb SL, et al. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007, 196:43.e1-43.e6.
339. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991, 324:1247-1252.
340. Sudfeld CR, Hewett PC, Abuelezam NN, et al. Herpes simplex virus type 2 cross-sectional seroprevalence and the estimated rate of neonatal infections among a cohort of rural Malawian female adolescents. Sex Transm Infect 2013, 89:561-567.
341. Brown ZA, Vontver LA, Benedetti J, et al. Genital herpes in pregnancy: risk factors associated with recurrences and asymptomatic viral shedding. Am J Obstet Gynecol 1985, 153:24-30.
342. Vontver LA, Hickok DE, Brown Z, et al. Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences. Am J Obstet Gynecol 1982, 143:75-84.
343. Brown ZA, Benedetti J, Selke S, et al. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Obstet Gynecol 1996, 87:483-488.
344. Chalhub EG, Baenziger J, Feigen RD, et al. Congenital herpes simplex type II infection with extensive hepatic calcification, bone lesions and cataracts: complete postmortem examination. Dev Med Child Neurol 1977, 19:527-534.
345. Hain J, Doshi N, Harger JH Ascending transcervical herpes simplex infection with intact fetal membranes. Obstet Gynecol 1980, 56:106-109.
346. Abrams C Isolation of herpes simplex from a mother and aborted fetus. Ghana Med J 1966, 5:41.
347. Kulhanjian JA, Soroush V, Au DS, et al. Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med 1992, 326:916-920.
348. Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992, 15:1031-1038.
349. Kropp RY, Wong T, Cormier L, et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006, 117:1955-1962.
350. Gibbs RS, Mead PB Preventing neonatal herpes-current strategies. N Engl J Med 1992, 326:946-947.
351. Rouse DJ, Stringer JS Cesarean delivery and risk of herpes simplex virus infection. JAMA 2003, 289:2208.
352. Brown EL, Gardella C, Malm G, et al. Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand 2007, 86:523-529.
353. Corey L, Wald A Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009, 361:1376-1385.
354. Gardella C, Brown Z, Wald A, et al. Poor correlation between genital lesions and detection of herpes simplex virus in women in labor. Obstet Gynecol 2005, 106:268-274.
355. Frenkel LM, Brown ZA, Bryson YJ, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 1991, 164:569-576.
356. Watts DH, Brown Z, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for reduction of herpes simplex virus shedding and cesarean section. Am J Obstet Gynecol 2003, 188:836-843.
357. Sheffield J, Hill J, Hollier L, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol 2006, 108:141-147.
358. Hollier L, Wendel G Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 2008, (1).
359. Scott L, Alexander J Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J Perinatol 1998, 15:57-62.
360. Gardella C, Brown Z, Wald A, et al. Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol 2005, 193:1891-1899.
361. Barnabas R, Carabin H, Garnett G The potential role of suppressive therapy for sex partners in the prevention of neonatal herpes: a health economic analysis. Sex Transm Infect 2002, 78:425-429.
362. Mark KE, Kim HN, Wald A, et al. Targeted prenatal herpes simplex virus testing: can we identify women at risk of transmission to the neonate?. Am J Obstet Gynecol 2006, 194:408-414.
363. Kaushic C, Ashkar AA, Reid LA, et al. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003, 77:4558-4565.
364. Corey L, Huang ML, Selke S, et al. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol 2005, 76:350-355.
365. Cowan FM, French RS, Mayaud P, et al. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect 2003, 79:286-290.
366. Lee FK, Coleman RM, Pereira L, et al. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 1985, 22:641-644.
367. Ashley RL, Wu L, Pickering JW, et al. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998, 36:294-295.
368. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988, 26:662-667.
369. Morrow R, Friedrich D, Meier A, et al. Use of "Biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005, 5:84.
370. Ngo T, Laeyendecker O, La H, et al. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clin Vaccine Immunol 2008, 15:382-384.
371. Martins TB, Woolstenhulme RD, Jaskowski TD, et al. Comparison of four enzyme immunoassays with a Western blot assay for the determination of type-specific antibodies to herpes simplex virus. Am J Clin Pathol 2001, 115:272-277.
372. Turner KR, Wong EH, Kent CK, et al. Serologic herpes testing in the real world: validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex Transm Dis 2002, 29:422-425.
373. Ashley R, Cent A, Maggs V, et al. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991, 115:520-526.
374. Morrow RA, Friedrich D Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2. Am J Clin Pathol 2003, 120:839-844.
375. Page J, Taylor J, Tideman RL, et al. Is HSV serology useful for the management of first episode genital herpes?. Sex Transm Infect 2003, 79:276-279.
376. Dorsky DI, Crumpacker CS Drugs five years later: acyclovir. Ann Intern Med 1987, 107:859-874.
377. Schaeffer HJ, Beauchamp L, de Miranda P, et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978, 272:583-585.
378. Crumpacker CS, Schnipper LE, Zaia JA, et al. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother 1979, 15:642-645.
379. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984, 310:1551-1556.
380. Mindel A, Faherty A, Carney O, et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988, 1:926-928.
381. Raborn GW, McGaw WT, Grace M, et al. Treatment of herpes labialis with acyclovir: review of three clinical trials. Am J Med 1988, 85:39-42.
382. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984, 251:2103-2107.
383. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993, 118:268-272.
384. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002, 34:944-948.
385. Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008, 43:190-195.
386. Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex Health 2008, 5:219-225.
387. Sacks SL, Aoki FY Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir. Clin Drug Investig 2005, 25:803-809.
388. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996, 276:44-49.
389. Laiskonis A, Thune T, Neldam S, et al. Valacyclovir in the treatment of facial herpes simplex virus infection. J Infect Dis 2002, 186(suppl 1):S66-S70.
390. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998, 178:603-610.
391. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995, 39:2759-2764.
392. Strand A, Patel R, Wulf HC, et al. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002, 78:435-439.
393. Romanowski B, Marina RB, Roberts JN Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003, 30:226-231.
394. Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 2002, 30:945-951.
395. Fife KH, Almekinder J, Ofner S A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis 2007, 34:297-301.
396. Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994, 169:1338-1341.
397. Bavaro J, Drolette L, Koelle D, et al. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis 2008, 35:383-386.
398. Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003, 47:1072-1080.
399. Spruance S, Aoki FY, Tyring S, et al. Short-course therapy for recurrent genital herpes and herpes labialis. J Fam Pract 2007, 56:30-36.
400. Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008, 47:651-658.
401. Sacks SL, Wanklin RJ, Reece DE, et al. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?. Ann Intern Med 1989, 111:893-899.
402. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989, 320:293-296.
403. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990, 112:416-422.
404. Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196:266-270.
405. Gupta R, Hill E, McClernon D, et al. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis 2005, 192:1102-1107.
406. Chibo D, Mijch A, Doherty R, et al. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. J Clin Virol 2002, 25:165-170.
407. McLaren C, Corey L, Dekket C, et al. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis 1983, 148:868-875.
408. Lehrman SN, Douglas JM, Corey L, et al. Recurrent genital herpes and suppressive oral acyclovir therapy: relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 1986, 104:786-790.
409. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994, 38:1246-1250.
410. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991, 325:551-555.
411. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997, 176:892-898.
412. Mendel DB, Barkhimer DB, Chen MS Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995, 39:2120-2122.
413. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994, 18:570-578.
414. Perkins N, Nisbet M, Thomas M Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect 2011, 87:292-295.
415. Schacker TW, Conant M, Thoming C, et al. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2002, 46:3243-3248.
416. Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010, 65:1733-1741.
417. Field H, Huang M, Lay E, et al. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir. Antiviral Res 2013, 100:297-299.
418. Katsumata K, Weinberg A, Chono K, et al. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 2012, 56:3587-3591.
419. Wald A, Corey L, Timmler B, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 2014, 370:201-210.
420. Richards J, Krantz E, Selke S, et al. Healthcare seeking and sexual behavior among patients with symptomatic newly acquired genital herpes. Sex Transm Dis 2008, 35:1015-1021.
421. Catotti DN, Clarke P, Catoe KE Herpes revisited: still a cause of concern. Sex Transm Dis 1993, 20:77-80.
422. Strachan E, Saracino M, Selke S, et al. The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. Brain Behav Immun 2011, 25:1475-1481.
423. Wald A, Langenberg A, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005, 143:707-713.
424. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366:34-43.
425. Schmidt OW, Fife KH, Corey L Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis 1984, 149:645-646.
426. Szpara ML, Parsons L, Enquist LW Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol 2010, 84:5303-5313.
427. Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196:266-270.
428. Roizman B, Knipe DM Herpes Simplex Viruses and Their Replication 2007, Lippincott Williams & Wilkins, Philadelphia. 5th ed.
429. Schiffer JT, Corey L Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 2013, 19:280-290.
430. Xu F, Sternberg M, Kottiri B, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
431. Bernstein DI, Bellamy AR, Hook EW, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013, 56:344-351.
432. Weiss H Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004, 11(suppl 1):24A-35A.
433. Corey L, Wald A, Celum C, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004, 35:435-445.
434. Cherpes TL, Meyn LA, Krohn MA, et al. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis 2003, 30:405-410.
435. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999, 341:1432-1438.
436. Wald A, Langenberg A, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001, 285:3100-3106.
437. Tobian AA, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis 2009, 199:945-949.
438. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
439. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985, 12:33-39.
440. Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006, 194:42-52.
441. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360:1298-1309.
442. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000, 342:844-850.
443. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509-515.
444. Quinn TC, Corey L, Chaffee RG, et al. The etiology of anorectal infections in homosexual men. Am J Med 1981, 71:395-406.
445. Schiffer JT, Swan D, Al Sallaq R, et al. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. Elife 2013, 2:e00288.
446. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141-1149.
447. Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature 2013, 497:494-497.
448. Cunningham AL, Turner RR, Miller AC, et al. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest 1985, 75:226-233.
449. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997, 99:1092-1097.
450. Brown Z, Wald A, Morrow R, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203-209.
451. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983, 98:958-972.
452. Benedetti J, Corey L, Ashley R Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994, 121:847-854.
453. Amir J, Harel L, Smetana Z, et al. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol 1999, 16:259-263.
454. Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N Engl J Med 1983, 308:916-921.
455. Stamm WE, Wagner KF, Amsel R, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980, 303:409-415.
456. Schlesinger Y, Tebas P, Gaudreault-Keener M, et al. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995, 20:842-848.
457. Nahmias AJ Disseminated herpes-simplex-virus infections. N Engl J Med 1970, 282:684-685.
458. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection: influence of site of infection and viral type. N Engl J Med 1987, 316:1444-1449.
459. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003, 188:1345-1351.
460. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis 2011, 203:180-187.
461. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988, 157:1169-1177.
462. Whitley RJ, Lakeman F Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995, 20:414-420.
463. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718-1725.
464. Freeman E, Weiss H, Glynn J, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73-83.
465. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109-2119.
466. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982, 96:265-269.
467. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991, 324:450-454.
468. Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 2011, 365:1284-1292.
469. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988, 26:662-667.
470. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993, 118:268-272.
471. Fife KH, Almekinder J, Ofner S A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis 2007, 34:297-301.
472. Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010, 65:1733-1741.
473. Field H, Huang M, Lay E, et al. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir. Antiviral Res 2013, 100:297-299.
474. Katsumata K, Weinberg A, Chono K, et al. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 2012, 56:3587-3591.
475. Wald A, Corey L, Timmler B, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 2014, 370:201-210.
476. Wald A, Langenberg A, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005, 143:707-713.